News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 15, 2015, 11:07 ET

Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary...

Jun 30, 2015, 08:00 ET
STIOLTO RESPIMAT

STIOLTO™ RESPIMAT® Now Available in the United States for the Treatment of COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray...

Jun 22, 2015, 08:00 ET

Idarucizumab* Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the...

Jun 16, 2015, 08:30 ET

Phase I Data Published in The Lancet Show Boehringer Ingelheim's Idarucizumab* Reverses Anticoagulant Effects of Dabigatran

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that The Lancet published results from a phase I study investigating the effects of...

May 31, 2015, 09:24 ET

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

 Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy...

May 27, 2015, 07:30 ET
Eli Lilly and Company logo.

Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association's 75th Scientific Sessions®

 The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim (BIPI) and Eli Lilly and Company (NYSE:...

May 26, 2015, 08:00 ET
STIOLTO RESPIMAT

FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium...

May 20, 2015, 11:30 ET

New Data Analyses on Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared to Tiotropium and Olodaterol Alone

Boehringer Ingelheim Pharmaceuticals, Inc. today announced new data analyses from the pivotal Phase III TONADO™ 1&2 studies...

May 18, 2015, 02:00 ET

Boehringer Ingelheim Presents New Data and Analyses Reinforcing the Safety and Efficacy of OFEV® (nintedanib) Capsules

Boehringer Ingelheim announced new data and analyses that provide further evidence to support the efficacy, safety and tolerability of OFEV®...

May 14, 2015, 08:00 ET

Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO with new data including presentation of Gilotrif® (afatinib) overall survival results for squamous cell carcinoma of the lung

 Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the Annual Meeting of the American...

May 11, 2015, 11:00 ET

Boehringer Ingelheim and Sutter Health Establish Research Collaboration to Improve Patient Care

Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern California, today...

May 05, 2015, 08:00 ET

Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that 29 abstracts from the company's respiratory portfolio will be presented at the...

Apr 23, 2015, 08:00 ET

FDA Grants Priority Review to Boehringer Ingelheim's Biologics License Application for Idarucizumab*

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the...

Apr 22, 2015, 08:00 ET

Majority of lung cancer treatment decisions are not guided by patient's genetic makeup, according to new international survey

 Despite the majority of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for genetic mutations, a gap still...

Apr 06, 2015, 08:00 ET

FDA Files Supplemental New Drug Application for Boehringer Ingelheim's Pradaxa® (dabigatran etexilate mesylate) for the Prophylaxis of Deep Venous Thrombosis and Pulmonary Embolism After Hip Replacement Surgery

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug...

Mar 23, 2015, 08:30 ET
Eli Lilly and Company logo

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

 Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across...

Mar 20, 2015, 13:01 ET
K. Alexander Papp, MD, PhD

Boehringer Ingelheim's Investigational Biologic Cleared Skin Better than Ustekinumab in Head-to-Head Phase II Psoriasis Study

For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066[*]. Nearly double the percentage of...

Mar 16, 2015, 08:00 ET

New Data from Boehringer Ingelheim's GLORIA™-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients at High Risk of Stroke May Be Undertreated

 Boehringer Ingelheim Pharmaceuticals, Inc. today will present results from two analyses of the GLORIA™-AF Registry Program examining the...

Mar 02, 2015, 08:00 ET

Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced it has submitted a biologics license application (BLA) to the U.S. Food and Drug...

Feb 21, 2015, 10:45 ET

New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function, Regardless of Allergic Status

 Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat® inhaler from five Phase III trials from...